Literature DB >> 21839114

Targeting chemokine receptors in chronic inflammatory diseases: an extensive review.

Pim J Koelink1, Saskia A Overbeek, Saskia Braber, Petra de Kruijf, Gert Folkerts, Martine J Smit, Aletta D Kraneveld.   

Abstract

The traffic of the different types of immune cells is an important aspect in the immune response. Chemokines are soluble peptides that are able to attract cells by interaction with chemokine receptors on their target cells. Several different chemokines and receptors exist enabling the specific trafficking of different immune cells. In chronic inflammatory disorders there is abundance of immune cells present at the inflammatory site. This review focuses on the role of chemokine receptors in chronic inflammatory disorders of the lungs, intestine, joints, skin and nervous system and the potential of targeting these receptors as therapeutic intervention in these disorders.
Copyright © 2011. Published by Elsevier Inc.

Mesh:

Substances:

Year:  2011        PMID: 21839114     DOI: 10.1016/j.pharmthera.2011.06.008

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  48 in total

Review 1.  Chemokines in Wound Healing and as Potential Therapeutic Targets for Reducing Cutaneous Scarring.

Authors:  Peter Adam Rees; Nicholas Stuart Greaves; Mohamed Baguneid; Ardeshir Bayat
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-11-01       Impact factor: 4.730

Review 2.  Chemokine Regulation of Neutrophil Infiltration of Skin Wounds.

Authors:  Yingjun Su; Ann Richmond
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-11-01       Impact factor: 4.730

3.  Elevated serum chemokines are independently associated with both endometriosis and uranium exposure.

Authors:  Alexis D Greene; Jessica A Kendziorski; Jeanette M Buckholz; Liang Niu; Changchun Xie; Susan M Pinney; Katherine A Burns
Journal:  Reprod Toxicol       Date:  2018-12-21       Impact factor: 3.143

4.  Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES.

Authors:  Pauline Bonvin; Franck Gueneau; Vanessa Buatois; Maud Charreton-Galby; Stanley Lasch; Marie Messmer; Urs Christen; Andrew D Luster; Zoë Johnson; Walter Ferlin; Marie Kosco-Vilbois; Amanda Proudfoot; Nicolas Fischer
Journal:  J Biol Chem       Date:  2017-01-30       Impact factor: 5.157

5.  Alternative C-terminal helix orientation alters chemokine function: structure of the anti-angiogenic chemokine, CXCL4L1.

Authors:  Je-Hung Kuo; Ya-Ping Chen; Jai-Shin Liu; Alexandre Dubrac; Cathy Quemener; Hervé Prats; Andreas Bikfalvi; Wen-guey Wu; Shih-Che Sue
Journal:  J Biol Chem       Date:  2013-03-27       Impact factor: 5.157

6.  Chemokine CXCL1 dimer is a potent agonist for the CXCR2 receptor.

Authors:  Aishwarya Ravindran; Kirti V Sawant; Jose Sarmiento; Javier Navarro; Krishna Rajarathnam
Journal:  J Biol Chem       Date:  2013-03-11       Impact factor: 5.157

7.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

8.  The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells.

Authors:  Wei Bin Fang; Min Yao; Iman Jokar; Nabil Alhakamy; Cory Berkland; Jin Chen; Dana Brantley-Sieders; Nikki Cheng
Journal:  Breast Cancer Res Treat       Date:  2015-03-06       Impact factor: 4.872

9.  Pathway and mechanism of drug binding to chemokine receptors revealed by accelerated molecular simulations.

Authors:  Shristi Pawnikar; Yinglong Miao
Journal:  Future Med Chem       Date:  2020-06-09       Impact factor: 3.808

10.  Gene expression based evidence of innate immune response activation in the epithelium with oral lichen planus.

Authors:  Guy R Adami; Alexander C F Yeung; Grant Stucki; Antonia Kolokythas; Herve Y Sroussi; Robert J Cabay; Igor Kuzin; Joel L Schwartz
Journal:  Arch Oral Biol       Date:  2014-01-04       Impact factor: 2.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.